United States: The telepath company Hims & Hers brought attention by running a Super Bowl advertisement that promoted its version of semaglutide injection medication that costs less than Wegovy and Ozempic.
More about the news
Results from the company’s screening questionnaire indicate some patients received Metformin as their medical treatment instead of the expected drug.
The price of Metformin stands lower than GLP-1 treatments even though Hims & Hers sells non-FDA-regulated and compound versions of the drugs.
About Metformin
Metformin is an old drug. Lilac extracts served as the basis for this drug, which doctors allegedly prescribed in the 1700s for treating what the French termed “sweet urine disease” or diabetes.
The France-derived lilac extract remains the essential ingredient of this medication, which came into widespread use in Europe during the 1950s.
As a treatment mechanism, Metformin fights insulin insensitivity and decreases liver glucose production, which stands as the main type 2 diabetes symptom, Yahoo Life reported.
Wonderful features of the drug create opportunities to decelerate type 2 diabetes progressions while generating protective benefits for those who carry genetic risks of developing the disease.
In 1994, the United States Food and Drug Administration (FDA) authorized the commercial distribution of Metformin to treat patients with type 2 diabetes.
Metformin serves as an active medical treatment for patients between 18 months and 60 years with prediabetic conditions.
Scientific evidence indicates Metformin provides benefits for many different health problems.
The use of metformin medication by type 2 diabetes patients decreases their risk of dying from heart disease.
Metformin works as a therapeutic agent for treating gestational diabetes and polycystic ovarian syndrome, sharing the characteristics of high blood sugar and insulin resistance in females.
The potential to reduce the chance of cancer alongside slowing down dementia development and strokes and delaying age-related processes has influenced doctors to regard Metformin as a potential health breakthrough.
According to Dr. Arti Thangudu, an endocrinologist and founder of Complete Medicine, “Most of the data we see finds metformin to be fairly weight-neutral,” Yahoo News reported.